Hans K Hasselbalch

Hans K Hasselbalch

Clinical Professor

Member of:

  • Internal Medicine: Haematology


  1. 2019
  2. Published

    JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

    Czech, J., Cordua, S., Weinbergerova, B., Baumeister, J., Crepcia, A., Han, L., Maié, T., Costa, I. G., Denecke, B., Maurer, A., Schubert, C., Feldberg, K., Gezer, D., Brümmendorf, T. H., Müller-newen, G., Mayer, J., Racil, Z., Kubesova, B., Knudsen, T., Sørensen, A. L. & 7 others, Holmström, M., Kjær, L., Skov, V., Larsen, T. S., Hasselbalch, Hans Carl, Chatain, N. & Koschmieder, S., 2019, In: Leukemia. 33, 4, p. 995-1010

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?

    Elbæk, M. V., Sørensen, A. L. & Hasselbalch, Hans Carl, 2019, In: Annals of Hematology. 98, 1, p. 101-109

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Vascular diseases in patients with chronic myeloproliferative neoplasms: Impact of comorbidity

    Frederiksen, H., Szépligeti, S., Bak, M., Ghanima, W., Hasselbalch, Hans Carl & Christiansen, C. F., 2019, In: Clinical Epidemiology. 2019, 11, p. 955-967

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia

    Garabet, L., Ghanima, W., Monceyron Jonassen, C., Skov, V., Holst, R., Mowinckel, M., Hasselbalch, Hans Carl, A. Kruse, T., Thomassen, M., Liebman, H., Bussel, J. B. & Sandset, P. M., 2019, In: Platelets. 30, 2, p. 206-212

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

    Hasselbalch, Hans Carl & Holmström, M. O., 2019, In: Seminars in Immunopathology. 41, 1, p. 5-19

    Research output: Contribution to journalReviewResearchpeer-review

  7. Published

    Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

    Hasselbalch, Hans Carl, 2019, In: Haematologica. 104, 11, p. 2119-2125

    Research output: Contribution to journalEditorialResearch

  8. Published

    Cancer immune therapy for myeloid malignancies: present and future

    Holmström, M. O. & Hasselbalch, Hans Carl, 2019, In: Seminars in Immunopathology. 41, 1, p. 97-109

    Research output: Contribution to journalReviewResearchpeer-review

  9. Published

    Cancerimmunterapi til behandling af hæmatologisk cancer

    Holmström, M. O., Klausen, U., Jørgensen, N. G., Holmberg, S., Grauslund, J., Met, Ö., Svane, Inge Marie, Pedersen, Lars Møller, Knudsen, L. M., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2019, In: Ugeskrift for Laeger. 181, 10, 5 p., V06180421.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Neo-antigen specific memory T-cell responses in healthy individuals

    Holmström, M. O., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2019, In: OncoImmunology. 8, 7, 2 p., 1599640.

    Research output: Contribution to journalLetterResearchpeer-review

  11. Published

    Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy

    Holmström, M. O., Novotny, G. W., Petersen, J., Aaboe-Jørgensen, M., Hasselbalch, Hans Carl, Andersen, Mads Hald, Nielsen, S. L., Fassi, Daniel El & Schöllkopf, C., 2019, In: Leukemia and Lymphoma. 60, 13, p. 3296-3299

    Research output: Contribution to journalLetterResearchpeer-review

Previous 1...3 4 5 6 7 8 9 10 ...14 Next

ID: 2849472